| abstract |
Generally, the present disclosure relates to immunoglobulin-associated compositions (e.g., antibodies or antigen-binding fragments thereof) that can bind to, and neutralize, the activity of A33 protein. Antibodies according to the present technology are useful in methods of detecting and treating A33 positive cancer in a subject in need thereof. |